Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
RMD · NYSE · Healthcare
Fundamental quality
87
out of 100
Resmed Inc fits the profile of a quality compounder: it pairs high return on capital (ROE 23.4%) with wide margins (net margin 27.4%) and a business that keeps growing (11.5% a year). On fundamental quality it scores 87 out of 100, profiling it as a company with solid fundamentals. Its weakest area is its growth (revenue +11.5%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
ResMed dominates sleep-apnea devices: the CPAP machines and masks millions of people use every night to breathe properly while they sleep, plus software connecting patient and doctor. A recurring, quietly growing healthcare business.
EPS growth: 16.7% · Revenue growth: 11.5%
Net margin: 27.4% · ROE: 23.4% · ROIC: 27.5%
Net debt/EBITDA: -0.47x · FCF: 31.7%
Source: SEC EDGAR · TTM through 31/03/2026
The score includes +1 for dividend strength: 4 consecutive years of increases. Keeping that streak demands growing cash generation and balance-sheet discipline.
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 2,957 | 622 | 707 | 713 |
| 2021 | 3,197 | 475 | 634 | 360 |
| 2022 | 3,578 | 779 | 216 | 502 |
| 2023 | 4,223 | 898 | 574 | 1,213 |
| 2024 | 4,685 | 1,021 | 1,302 | 469 |
| 2025 | 5,146 | 1,401 | 1,662 | -541 |
Between 2020 and 2025, revenue went from $2,957M to $5,146M (+74%) and net income went from $622M to $1,401M (+125%). Meanwhile, its margins have widened (from 21% to 27%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the nine months ended March 31, 2026, versus the nine months ended March 31, 2025 (SEC filings):
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$2.12
per share, yearly
22.2% of earnings
Payout
4 straight years raising it
Growth
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Resmed Inc cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Resmed Inc a good company to invest in?
In terms of business quality, Resmed Inc scores 87 out of 100 in our analysis, placing it as a company of high fundamental quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Resmed Inc a profitable company?
Very. Resmed Inc shows a net margin of 27.4% and an ROE of 23.4%, typical of a highly profitable business.
Does Resmed Inc have a lot of debt?
No. Resmed Inc has a net cash position: more cash than debt.
Is Resmed Inc growing?
Its revenue has grown 11.5% annualized in recent years and its earnings per share 16.7%, and without interruption since 2020.
Does Resmed Inc generate cash?
Yes. It converts about 31.7% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Recursion Pharmaceuticals (RXRX) · Eli Lilly (LLY) · UnitedHealth (UNH) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · see more →
Who's behind the methodology and model · how the score is computed
Data: see Resmed Inc's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.